Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Punctum Plug · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| OTX-DP (Dexamethasone Punctum Plug) | ACTIVE_COMPARATOR | Resorbable hydrogel drug delivery vehicle containing dexamethasone |
| PVPP (Placebo Punctum Plug) | PLACEBO_COMPARATOR | Resorbable hydrogel drug delivery vehicle containing no drug |
| Name | Type | Description |
|---|---|---|
| Dexamethasone | DRUG | - |
| Punctum Plug | DRUG | - |
Inclusion Criteria: * Has a cataract and is expected to undergo clear corneal cataract surgery with phacoemulsification and implantation of a posterior chamber intraocular lens * Has a potential post-operative pinhole corrected Snellen VA of at least 20/200 or better in both eyes Exclusion Criteri...
Punctum Plug is an investigational small molecule being developed for post ocular surgical inflammation and pain. It is designed to treat inflammation and pain that occur after ocular surgery. The drug is currently in Phase 3 clinical development and is not yet approved by regulatory authorities.
Punctum Plug is a small molecule developed by Ocular Therapeutix, Inc. (OCUL) for the treatment of post ocular surgical inflammation and pain. The specific molecular target of Punctum Plug has not been disclosed in the available information.
Punctum Plug is being developed by Ocular Therapeutix, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol OCUL. The company is conducting clinical trials to evaluate the safety and efficacy of Punctum Plug for post ocular surgical inflammation and pain.
Punctum Plug is in Phase 3 clinical development. It is an investigational drug and has not been approved by the FDA. A Phase 3 study evaluating its safety and efficacy for ocular inflammation and pain after cataract surgery has been completed.
Punctum Plug has one completed Phase 3 clinical trial, identified as NCT02034019. This study evaluated the safety and efficacy of OTX-DP for the treatment of ocular inflammation and pain after cataract surgery. The trial enrolled 247 participants in the United States and was randomized, double-blind, and placebo-controlled.
Yes, Punctum Plug is also known as OTX-DP. The Phase 3 clinical trial NCT02034019, which evaluated the safety and efficacy of OTX-DP for ocular inflammation and pain after cataract surgery, is the trial for Punctum Plug.